Ocular Therapeutix, Inc. (OCUL)
10.49
-0.13
(-1.22%)
USD |
NASDAQ |
Sep 11, 16:00
10.42
-0.07
(-0.67%)
After-Hours: 05:44
Ocular Therapeutix Enterprise Value : 1.784B for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 1.784B |
| September 10, 2026 | 1.813B |
| September 09, 2026 | 1.999B |
| September 08, 2026 | 1.977B |
| September 04, 2026 | 1.817B |
| September 03, 2026 | 1.817B |
| September 02, 2026 | 1.874B |
| September 01, 2026 | 1.802B |
| August 31, 2026 | 1.784B |
| August 28, 2026 | 1.756B |
| August 27, 2026 | 1.857B |
| August 26, 2026 | 1.846B |
| August 25, 2026 | 1.870B |
| August 24, 2026 | 1.848B |
| August 21, 2026 | 1.914B |
| August 20, 2026 | 1.916B |
| August 19, 2026 | 2.057B |
| August 18, 2026 | 1.898B |
| August 17, 2026 | 1.819B |
| August 14, 2026 | 1.685B |
| August 13, 2026 | 1.699B |
| August 12, 2026 | 1.727B |
| August 11, 2026 | 1.624B |
| August 10, 2026 | 1.510B |
| August 07, 2026 | 1.499B |
| Date | Value |
|---|---|
| August 06, 2026 | 1.400B |
| August 05, 2026 | 1.347B |
| August 04, 2026 | 1.367B |
| August 03, 2026 | 1.325B |
| July 31, 2026 | 1.275B |
| July 30, 2026 | 1.341B |
| July 29, 2026 | 1.317B |
| July 28, 2026 | 1.336B |
| July 27, 2026 | 1.378B |
| July 24, 2026 | 1.348B |
| July 23, 2026 | 1.374B |
| July 22, 2026 | 1.366B |
| July 21, 2026 | 1.442B |
| July 20, 2026 | 1.393B |
| July 17, 2026 | 1.450B |
| July 16, 2026 | 1.493B |
| July 15, 2026 | 1.668B |
| July 14, 2026 | 1.611B |
| July 13, 2026 | 1.650B |
| July 10, 2026 | 1.721B |
| July 09, 2026 | 1.795B |
| July 08, 2026 | 1.736B |
| July 07, 2026 | 1.749B |
| July 06, 2026 | 1.602B |
| July 02, 2026 | 1.598B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| EyePoint, Inc. | 201.37M |
| Merck & Co., Inc. | 402.09B |
| Theravance Biopharma, Inc. | 566.37M |
| LENZ Therapeutics, Inc. | -77.43M |
| ANI Pharmaceuticals, Inc. | 1.847B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -78.76M |
| Revenue (Quarterly) | 13.48M |
| Total Expenses (Quarterly) | 92.24M |
| EPS Diluted (Quarterly) | -0.3501 |
| Gross Profit Margin (Quarterly) | 85.08% |
| Profit Margin (Quarterly) | -584.5% |
| Earnings Yield | -13.47% |
| Normalized Earnings Yield | -13.50 |